Member Info for Latino

Also financing RNS did say they could not trade beyond this month (April) without the financing! Hence we are now 10 days in so most certainly funding is already secured and Alex very keen and straight in head down…forgot the RNS lol!

Not to RNSd is very strange as this is material news - Alex??
However many articles online have confirmed they have secured the funds so not sure why no RNS?

-- a tranche of GBP6,000,000 principal amount of Loan Notes (the "Additional A Notes") to be issued to Gatemore Investment Partners I LP , Lansdowne and MNL (Hambro Perks) Nominees Limited ("Hambro Perks") (the "Additional A Note Purchasers") on or around 21 April 2022; and

Our new CEO appears too busy with the restructure and sale of parts of business. Striking think is no GM RNS which was due last week according to last RNS…so it appears though new CEO is having a re-think / on delisting / sale ??

Project Icewine - Independent Third-Party Mapping Complete,

About to go again…

Relentless buying….MMs won’t be able to hold this down for long!

Now

Should get back to 0.2 now…gla

Pressure canister or even coiled spring good analogy…the CEO is hard at work from the looks of it to turn this around so early shoots of positivity are certainly appearing..

Potential here is massive and Alex Snow knows this, Gatemore are backing Alex clearly so it is highly likely the strategy outlined in this letter will be followed with a some minor changes. I.e. retain LSE listing and go for dual listing on NASDAQ..

This letter was written on SP of 151p on 21/07/21 (now 1.8p!), PEELs price target at this time was 310-349p with a bill case prediction of 921p…ie suggesting this had potential to go to 921p!

Meant to highlight this para:

Sensyne is a British company and due to its important relationships with NHS Trusts, it should maintain its listing in the UK. Nonetheless, a secondary listing on NASDAQ will provide the Company and its investors multiple and immediate benefits:

…and this is why they will block the listing in the GM…in their own words in the letter:

‘.. Unlocking Value
We believe there have been two key issues holding back Sensyne’s share price.
Firstly, the “Woodford overhang” which became the “Acacia overhang”. As was widely publicised, the collapse of Woodford Investment Management (one of the largest investors in Sensyne) left other investors concerned over how that stake would be liquidated. Those concerns were put to rest when Acacia purchased the position, however, over time the market grew increasingly concerned about their intentions as well. The good news is that as of three weeks ago Acacia filed a TR-1 indicating they have fully divested their position.
Secondly, and most critically, has been the lack of access to the right investor base. Although AIM may have been an appropriate launch point for the business a few years ago, the Company’s ambitions have clearly outgrown the junior market today. We believe that the most expedient path for the business to become the recognised leader in clinical AI, and a top player in digital health, is to access the deeper pools of healthcare and growth-oriented capital available on NASDAQ.
Sensyne is a British company and due to its important relationships with NHS Trusts, it should maintain its listing in the UK. Nonetheless, a secondary listing on NASDAQ will provide the Company and its investors multiple and immediate benefits:
? accesstothelargestandleadinggrowth-focusedmarket:NASDAQistheleadinggrowthstock exchange in the world and features 980 healthcare stocks (30% of the index) vs. 80 on the AIM (10% of the index)8;
? accesstodeeperpoolsofcapitalandpotentialinvestors:NASDAQissupportedbydeeppools of capital and a diverse range of long-term growth investors;
? higher valuation: companies listed on NASDAQ typically trade at materially higher valuation multiples (see below);
? higherliquidity:stockslistedonNASDAQbenefitfromsignificantlyhigherliquidity(seebelow); and
? broader healthcare focused research coverage: enhanced company profile with US-based specialist healthcare analyst….’

Worth a read just shows what difference a year makes…less than a year ago bull case valuation touted by Gatemore/Peel was 921p…yes £9.21!!!! This is what Gatemore said in all letter to company…

https://gatemore.com/wp-content/uploads/2021/07/Gatemore-Letter-to-Sensyne.pdf

Key extract ‘…The digital healthcare industry is currently drawing high levels of attention and new capital. There have been several recent noteworthy consolidations and fund raisings relevant to Sensyne, including the $7 billion merger of Datavant and Ciox Health, intended to create a leading healthcare data ecosystem for anonymised patient-level data. This is further validation of the tail winds behind Sensyne’s industry. We also note other early-stage healthcare AI companies (such as 23andme, Exscientia, Insilico Medicine, Komodo Health and Tempus) have each recently raised capital at valuations in the $1.5 – $8.8 billion range4 (representing 5x – 30x Sensyne’s valuation).
Furthermore, Liberum and Peel Hunt have published a number of reports5 highlighting the underlying value of the business, with recent price targets of 310p and 349p, respectively, indicating 120% – 150% upside from current trading6. Peel Hunt has outlined a bull case with a price target of 921p7 suggesting 550% upside.
However, and despite Sensyne’s recent achievements, we believe that the Company remains significantly undervalued. While Sensyne now has one of the most valuable patient datasets globally, on an enterprise value to patient record basis, the Company trades amongst the cheapest of its peers — not even considering the significant value of Sensyne’s app platform and the SENSE clinical algorithm engine business line.

As Sensyne completes the curation of its dataset, its targeted valuation should align with these comparable valuations, which is an uplift of 8x to 150x..’

https://gatemore.com/wp-content/uploads/2021/07/Gatemore-Letter-to-Sensyne.pdf

Any dip in volume and MMs not missing an opportunity to shake this down, soon they will not have choice when 2nd TR-1 lands so taking full advantage to flush the weak and load as they know high premiums will be paid later…

Yesterday tr-1 was a massive step in this saga, hence why we should see a big reversal here…patience whilst MMs shake on any weakness is key!

Recovery /re-rate has started with Gatmore showing their hand already yesterday…so yep expecting more Tr-1’s. MMs will shake whilst they can!

Under 2p again to buy…market digressing!

Selling can be good for SP especially as we come to close. Alow MMs to flush weak and traders out! Most of us know next news could see a massive re-rate correction here. Patience is the name of the game I think!

Unlikely, cos GM is not even announced yet! Imagine Alex secured buyers for parts of the business!

Yep agree MMs playing their games, but today we have an RNS where one of the big investors is now showing it’s hand indicating full backing of new CEO…Further RNS due as we’ve already been told this week.